comprehensive -WSS

comprehensive

author：focus 2025-09-28 23:47:25 - browse：3248

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Paxlovid rebound happens. Why and to whom are still a mystery

hotspot

WSS

Slovenia has suffered its worst

Feed a cold, starve a fever? Here’s what science says

A pediatrician calls for Congress to pass the child tax credit deal

Future doctors need a strong humanities education

To bolster infectious disease surveillance, genomics powerhouses team up

What causes osteoarthritis? Researchers study link to brain protein

explore

comprehensive

explore

Alkermes shareholders re

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

ChatGPT in medicine: STAT answers readers' burning questions

Tuberculosis patients need more than just free medication

Duchenne breakthrough therapy leaves behind pioneering families

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Continuity nursing helped my family in our darkest PICU moments

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

How one medical school became remarkably diverse

Microsoft launches AI tool for clinical documentation through Epic

hotspot

With heat waves through August, officials warn of health risks

The inclusion problem at the heart of rehabilitation research

Flash flood warnings continue for parts of Missouri, Illinois

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Failure, not just success, should guide future doctors

hotspot

hotspot

focus

entertainment